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REVIEW Open Access
Role of modern immunotherapy in
gastrointestinal malignancies: a review of
current clinical progress
Zin W. Myint and Gaurav Goel*
Abstract
Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge disease burden worldwide.
There is clearly a significant unmet need for new drugs and therapies to further improve the treatment outcomes
of GI malignancies. Immunotherapy is a novel treatment strategy that is emerging as an effective and promising
treatment option against several types of cancers. CTLA-4 and PD-1 are critical immune checkpoint molecules that
negatively regulate T cell activation via distinct mechanisms. Immune checkpoint blockade with antibodies directed
against these pathways has already shown clinical efficacy that has led to their FDA approval in the treatment of
several solid tumors including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and
head and neck cancer. This review will summarize the current clinical progress of modern immunotherapy in the
field of GI tumors, with a special focus on immune checkpoint blockade.
Keywords: Immunotherapy, Immune checkpoint blockade, PD-1, PD-L1, CTLA-4, Gastrointestinal cancers,
Esophageal cancer, Gastric cancer, Colorectal cancer, Pancreatic cancer, Hepatocellular carcinoma
Background
Gastrointestinal (GI) cancers are a group of highly ag-
gressive malignancies with a huge disease burden world-
wide. Despite the progress made in the field of cancer
therapeutics, there is clearly a significant unmet need for
new drugs and therapies to improve upon the efficacy of
available anticancer agents and reduce the toxicity of
current regimens, with an overall goal of improving the
treatment outcomes of GI malignancies.
Immunotherapy is a novel treatment strategy that is
emerging as an effective and promising treatment option
against several types of cancers. Sir William Coley was
the first to use a bacterial immunotoxin to treat a pa-
tient with neck sarcoma in 1898 [1]. More recently dur-
ing the last decade, immunotherapy has shown
encouraging results in various tumor types. This pro-
gress is largely attributed to identification of new
immune-based targets, coupled with our enhanced un-
derstanding of tumor immunology and the tumor
microenvironment [2]. Cytotoxic T lymphocyte protein-
4 (CTLA-4) and programmed cell death protein-1 (PD-
1) are critical immune checkpoint molecules that nega-
tively regulate T cell activation via distinct mechanisms.
CTLA-4 is a co-inhibitory molecule expressed on acti-
vated T cells and T regulatory (Treg) cells. Interaction of
the CTLA-4 receptor on T cells with its B7-1/B7-2 li-
gands on antigen-presenting cells (APCs) inhibits the
CD28-mediated T cell stimulatory signal [3]. The inhib-
ition of this receptor-ligand interaction using an anti-
CTLA-4 antibody results in the reactivation and prolifer-
ation of T cells and also decreases the immunosuppres-
sive Treg cells in the tumor microenvironment [4]. The
anti-CTLA-4 antibody ipilimumab is currently approved
for the treatment of melanoma. PD-1 is a co-inhibitory
receptor expressed on the surface of activated T cells,
Treg cells, and monocytes. It interacts with its two li-
gands, PD-L1 and PD-L2, to provide an inhibitory signal
in T cell activation, leading to downregulation of cellular
and humoral immune responses [5–7]. Increasing evi-
dence suggests that targeting the PD-1/PD-L pathway is
an effective therapeutic strategy to enhance the antitu-
mor immune response. Antibody-mediated blockage of
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PD-1 or PD-L1 results in the inhibition of this checkpoint,
leading to T cell activation and enhanced antitumor activ-
ity [8, 9]. PD-1 pathway inhibitors are currently approved
by the Food and Drug Administration (FDA) for the treat-
ment of several solid tumors including melanoma, non-
small cell lung cancer (NSCLC), renal cell carcinoma
(RCC), urothelial carcinoma, and head and neck cancer.
Additional potentially targetable checkpoints such as
OX40, TIM3, and LAG3 are also being evaluated in on-
going preclinical and clinical studies.
This review will summarize the current clinical pro-
gress of modern immunotherapy in the treatment of
various GI malignancies, with a special focus on immune
checkpoint blockade.
Esophageal and gastric cancers
Cancers of the upper GI tract are a group of highly ag-
gressive malignancies. In the USA alone, 16,910 new
cases of esophageal cancer and 26,370 cases of stomach
cancer are estimated to be diagnosed in 2016, and ap-
proximately 15,690 and 10,730 deaths will be attributed
to these diseases, respectively [10]. It is now well recog-
nized that there exists an urgent unmet need to identify
effective novel strategies for the treatment of these pa-
tients that are aimed at improving the clinical outcomes
beyond the activity of the existing approaches. Targeting
the immune checkpoint pathways to activate the host
immune system against cancer cells is one such novel
approach that is rapidly evolving in the recent years.
A comprehensive molecular characterization of gastric
adenocarcinoma as part of The Cancer Genome Atlas
(TCGA) project has identified four major genomic sub-
type of gastric cancer, namely, EBV-positive tumors,
microsatellite instability (MSI) tumors, genomically stable
tumors, and chromosomally unstable tumors [11, 12]. In
the EBV subgroup, there was amplification of JAK2,
CD274, and PDCD1LG2 [11]. CD274 and PDCD1LG2 en-
code PD-L1 and PD-L2, respectively, which suggests a po-
tential role of PD-1/PD-L1 pathway inhibitors in the
treatment of gastric cancer.
High expression of PD-L1 is associated with a poor
prognosis in esophageal cancers. Ohigashi et al. studied
the role of PD-L1 and PD-L2 expression in 41 human
esophageal cancer resection specimens and demon-
strated that expression of either PD-L1 or PD-L2 is a
significant prognostic marker in patients with squamous
cell carcinoma of the esophagus [13]. A significant posi-
tive correlation between mRNA and protein expression
was observed for both PD-L1 and PD-L2. In this study
cohort, overall survival (OS) for PD-L1- or PD-L2-
positive patients was significantly worse than those ab-
sent for these markers (P = 0.025 and P = 0.003, respect-
ively). In multivariate analysis, the PD-L1 and PD-L2
status continued to remain a significant independent
prognostic factor (P = 0.0001). This led to the hypothesis
that PD-L status may be a critical factor to promote
tumor growth and metastasis in esophageal cancer. In
another study involving 101 distal esophageal adenocar-
cinoma primary resection specimens without preopera-
tive chemotherapy or radiotherapy, Loos et al.
demonstrated that high tumor PD-L1 expression was
significantly associated with poor survival (HR = 2.92; P
< 0.001) [14]. The prognostic significance of PD-L1 ex-
pression persisted even in multivariate analysis after
adjusting for the TNM stage and tumor grade. A similar
prognostic role of PD-L1 has been observed in gastric
cancer as well. Zheng et al. performed a retrospective
analysis using 80 advanced gastric cancer patients and
40 healthy controls, to evaluate the association between
circulating PD-L1 expression and prognosis [15]. Circu-
lating PD-L1 expression was tested by ELISA and was
found to be significantly upregulated in gastric cancer
patients compared to healthy controls. In the study by
Wu et al., it was shown that normal gastric tissues do
not express PD-L1, but it was detected in 42% of the
gastric cancer tissues [16]. The level of PD-L1 expression
by immunohistochemistry (IHC) significantly correlated
with tumor size, lymph node metastases, and patient
survival. Saito et al. investigated the PD-1 expression on
CD4+ and CD8+ T cells and its relationship with im-
mune evasion in gastric cancer patients [17]. The PD-1
expression on T cells from gastric cancer patients was
significantly higher than normal controls and was found
to be related to disease progression. The above data pro-
vides sufficient evidence to suggest that the PD-1/PD-L
pathway plays a critical role in the evasion of antitumor
host immune responses in esophageal and gastric can-
cers. Accordingly, developing therapies aimed at target-
ing this immune checkpoint pathway is a potentially
promising strategy that can lead to improvement in the
treatment outcomes for this devastating disease.
The multi-cohort, phase Ib KEYNOTE-012 trial was
one of the early studies to evaluate the safety and effi-
cacy of anti-PD-1 antibody pembrolizumab in previously
treated, PD-L1-positive, advanced solid tumors
(NCT01848834) [18]. The tumors were defined as PD-
L1-positive if the marker was present on ≥1% tumor
cells or if any positive staining was present in the
stroma. This gastric cancer cohort enrolled 39 patients
with PD-L1-positive recurrent or metastatic adenocar-
cinoma of the stomach or gastroesophageal junction
(GEJ). An overall response rate (ORR) of 22% (8 PR
(partial response)) was reported in 36 evaluable ad-
vanced gastric cancer patients. Pembrolizumab demon-
strated a manageable safety profile with grade 3–4
treatment-related adverse events (TRAEs) observed in
13% patients. In this study, no association was observed
between response and higher PD-L1 expression on
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tumor cells, as assessed with the clinical trial assay. In
another similar multi-cohort phase Ib trial, single-agent
pembrolizumab was evaluated in PD-L1-positive ad-
vanced solid tumors (KEYNOTE-028, NCT02054806).
The esophageal carcinoma cohort enrolled 23 patients
with squamous cell carcinoma (SqCC; 74%) or adenocar-
cinoma (22%) of the esophagus or GEJ, which had pro-
gressed on the standard therapies [19]. The primary
endpoint of ORR was estimated at 30% in this cohort of
heavily pretreated patients. At the time of data cutoff in
November 2015, four out of seven responses were still
ongoing and the median duration of response (DoR) had
not been reached. Single-agent pembrolizumab exhibited
a manageable toxicity profile with 17% of the patients
experiencing grade 3 TRAEs. The encouraging clinical
activity observed in these studies formed the basis for
larger phase II and III studies of anti-PD-1 therapies in
gastric, esophageal, and GEJ cancers.
KEYNOTE-059 is an ongoing phase II multi-cohort
study in recurrent or metastatic gastric or GEJ adenocar-
cinoma patients (NCT02335411). The three study co-
horts in this trial include pembrolizumab plus
fluoropyrimidine and cisplatin in treatment-naïve pa-
tients, pembrolizumab monotherapy in previously
treated patients, and pembrolizumab alone in previously
untreated patients. The preliminary safety data from the
pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin
combination cohort were presented at the 2016 Ameri-
can Society of Clinical Oncology (ASCO) annual meet-
ing [20]. At the time of data cutoff, 18 patients had been
treated with this combination regimen. Grade 3–4
TRAEs were noted in 67% patients, none of which were
attributed to pembrolizumab. Another ongoing phase II
trial is evaluating pembrolizumab as a monotherapy in
patients with previously treated advanced adenocarcin-
oma or SqCC of the esophagus or GEJ (KEYNOTE-180,
NCT02559687). Exploratory analyses in this study will
include evaluation of the immune-related gene expres-
sion profiles and PD-L1 expression status as predictors
of pembrolizumab efficacy.
Multiple phase III studies involving anti-PD-1 therapy
in gastric and esophageal cancers are currently in pro-
gress. KEYNOTE-061 is a randomized, open-label study
designed to compare the efficacy and safety of pembroli-
zumab versus standard-of-care paclitaxel in the second-
line treatment of metastatic or unresectable gastric or
GEJ adenocarcinoma (NCT02370498). KEYNOTE-062 is
another randomized phase III study containing three
arms which will compare the safety and efficacy of pem-
brolizumab monotherapy, versus 5-FU plus cisplatin,
versus all three agents combined together in the first-
line treatment of PD-L1-positive advanced gastric or
GEJ adenocarcinoma (NCT02494583). Another phase III
trial (KEYNOTE-181) will enroll approximately 600
patients to compare the efficacy of pembrolizumab rela-
tive to single-agent chemotherapy (paclitaxel, docetaxel,
or irinotecan) in patients with previously treated ad-
vanced adenocarcinoma or SqCC of the esophagus or
GEJ (NCT02564263).
Avelumab is a fully human anti-PD-L1 IgG1 antibody.
The safety and clinical activity of avelumab as a first-line
maintenance or second-line therapy in patients with ad-
vanced gastric or GEJ cancer were evaluated in the
phase Ib JAVELIN trial (NCT01772004) [21]. Of the 151
patients who have been treated with avelumab in this
study so far, grade ≥3 TRAEs were reported in 10% pa-
tients. There was one treatment-related death secondary
to hepatic failure/autoimmune hepatitis. The uncon-
firmed ORR was 10% (6 PR) in the second-line therapy
arm and 9% (2 CR, 6 PR) in the first-line maintenance
therapy arm. The disease control rate (DCR) was 29 and
57% and median progression-free survival (PFS) was 6
and 12 weeks in the two treatment arms, respectively.
Encouraged by the acceptable safety profile and promis-
ing clinical activity of single-agent avelumab, two large
randomized phase III trials of avelumab in gastric cancer
have been initiated (NCT02625623, NCT02625610).
Immune checkpoint inhibition with anti-CTLA-4 anti-
body has also been explored in the treatment of upper
GI tract cancers. Single-agent ipilimumab was evaluated
in a randomized phase II trial of previously treated pa-
tients with locally advanced or metastatic gastric and
GEJ cancers (NCT01585987) [22]. The study was termi-
nated early after the interim analysis due to the lack of
demonstrable clinical activity with ipilimumab. Combin-
ing anti-CTLA-4 and anti-PD-1 together is another po-
tential immunotherapeutic strategy that is being
explored in the ongoing CheckMate-032 trial
(NCT01928394). This phase I/II, open-label study is
evaluating the efficacy of nivolumab alone or in combin-
ation with ipilimumab, in chemotherapy-refractory ad-
vanced solid tumors. The three treatment arms in this
study include nivolumab 3 mg/kg, nivolumab 1 mg/kg
plus ipilimumab 3 mg/kg, and nivolumab 3 mg/kg plus
ipilimumab 1 mg/kg. The preliminary results from the
gastric cancer cohort (n = 160) demonstrated an ORR of
14, 26, and 10% in the three treatment arms, respectively
[23]. The grade 3–4 TRAEs occurred in 17, 45, and 27%
of patients, respectively.
Table 1 provides a summary of the selected ongoing im-
munotherapy clinical trials in various GI malignancies.
Colorectal cancer
Colorectal cancer (CRC) is a major public health prob-
lem in the USA and globally. In the USA, it is the sec-
ond leading cause of cancer mortality, and in 2016, it is
estimated that nearly 50,000 deaths will be attributed to
this disease [10]. Within the last decade itself, several
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Table 1 Summary of selected ongoing immunotherapy clinical trials in gastrointestinal malignancies
NCI identifier Study
phase
Study agent Mode of action of immunotherapy agent
Esophageal cancer
NCT02642809 0 Pembrolizumab + radiotherapy Anti-PD-1 Ab
NCT02735239 I/II Durvalumab + chemotherapy ± radiotherapy Anti-PD-L1 Ab
NCT02559687
(KEYNOTE-180)
II Pembrolizumab Anti-PD-1 Ab
NCT02644863,
NCT01691625





III Pembrolizumab vs. chemotherapy Anti-PD-1 Ab
Gastric cancer
NCT02443324 I Pembrolizumab + ramucirumab Anti-PD-1 Ab, anti-VEGFR2 Ab
NCT02310464 I OBI-833 Cancer vaccine
NCT02689284 Ib/II Pembrolizumab + margetuximab Anti-PD-1 Ab, anti-HER2-neu Ab
NCT02340975 Ib/II Tremelimumab vs. durvalumab vs. tremelimumab + durvalumab Anti-CTLA-4 Ab, anti-PD-L1 Ab
NCT02317471 I/II Autologous gp96 vaccination ± chemotherapy Heat shock protein purified from autologous
tumor cells
NCT02617134 I/II Anti-MUC1 CAR T cells Adoptive cellular therapy
NCT02862561,
NCT02873520
I/II Precision cell immunotherapy ± chemotherapy Dendritic cell suspension
NCT01783951 I/II DC-CIK + S-1 Adoptive cellular therapy
NCT02632201 I/II Pluripotent killer T cells expressing Ab for HER-2 (PIK-HER2) Adoptive cellular therapy
NCT02370498
(KEYNOTE-061)
III Pembrolizumab vs. paclitaxel Anti-PD-1 Ab
NCT02494583
(KEYNOTE-062)










III Avelumab + BSC vs. chemotherapy + BSC Anti-PD-L1 Ab
Colorectal cancer
NCT02512172 I Pembrolizumab + romidepsin and/or 5-azacitidine Anti-PD-1 Ab
NCT02856425 I Pembrolizumab + nintedanib Anti-PD-1 Ab
NCT02777710 I Durvalumab + CSF-1R TKI Anti-PD-L1 Ab
NCT02754856 I Durvalumab + tremelimumab Anti-PD-L1 Ab, anti-CTLA-4 Ab
NCT02559024 I MEDI6469 Anti-OX40 Ab
NCT01890213 I AVX701 CEA-based cancer vaccine
NCT02617134 I/II Anti-MUC1 CAR T cells Adoptive cellular therapy
NCT02900664 Ib PDR001 + either CJM112 or EGF816 or canakinumab or trametinib Anti-PD-1 Ab
NCT02460198
(KEYNOTE-164)
II Pembrolizumab Anti-PD-1 Ab
NCT02860546 II Nivolumab + TAS-102 Anti-PD-1 Ab
NCT02466906 II RhGM-CSF Recombinant human GM-CSF
NCT02448173 III OncoVAX + surgery Cancer vaccine
NCT02563002
(KEYNOTE-177)
III Pembrolizumab vs. chemotherapy Anti-PD-1 Ab
NCT02788279 III Atezolizumab ± cobimetinib vs. regorafenib Anti-PD-L1
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new drugs (regorafenib, ramucirumab, TAS-102) have
been approved by the FDA for the treatment of CRC,
but the magnitude of clinical benefit with these
agents has continued to remain modest [24–28]. Con-
sequently, novel treatment strategies such as immuno-
therapy are being evaluated to further improve the
outcomes of this disease.
Almost a decade ago, Galon and colleagues demon-
strated that the type, density, and distribution of im-
mune cells inside colorectal tumors can predict the
clinical outcome more accurately than the conventional
TNM staging [29]. In this study, the numbers of total T
cells (CD3+), cytotoxic effector T cells (CD8+), and
memory T cells (CD45RO+) were evaluated in the tumor
core and at the invasive margin. The investigators dem-
onstrated that tumors with high levels of CD3+ T cells in
the core as well as at the invasive margin were associ-
ated with the best clinical outcome, independent of the
TNM stage. In a subsequent study, the prognostic role
of tumor-infiltrating lymphocytes (TILs) was also dem-
onstrated in metastatic CRC lesions [30]. In this study,
high TIL density in the metastatic sites conferred a
greater response to chemotherapy treatment and was as-
sociated with a longer PFS. In an effort to promote
quantification of the immune infiltrate inside the tumor,
the “Immunoscore” methodology has been defined [31].
Recently, in a worldwide consortium-based analysis of
1,336 stage I/II/III colon cancer patients, the standard-
ized immunoscore assay was validated as a prognostic
marker, and a “high” immunoscore was found to be as-
sociated with longer time-to-tumor recurrence [32].
It is now well established that two distinct immuno-
logic subtypes of CRC exist, according to the mismatch
repair (MMR) status, namely, MMR-proficient and
MMR-deficient. Microsatellite instability (MSI) in colo-
rectal tumors occurs either due to a germline mutation
Table 1 Summary of selected ongoing immunotherapy clinical trials in gastrointestinal malignancies (Continued)
NCT02280278 III CIK Cytokine-induced killer cells
Pancreatic cancer
NCT02734160 I Durvalumab + galunisertib Anti-PD-L1 Ab
NCT02529579 I/II Gemcitabine ± iAPA-DC/CTL Adoptive cellular therapy
NCT02718859 I/II NK cells + irreversible electroporation Natural killer cells
NCT02305186 I/II Chemoradiation ± pembrolizumab Anti-PD-1 Ab
NCT01781520 I/II DC-CIK + S-1 Adoptive cellular therapy
NCT01896869 II FOLFIRINOX + ipilimumab + allogeneic GM-CSF vaccine Anti-CTLA-4 Ab, vaccine
NCT02648282 II Cyclophosphamide + pembrolizumab + GVAX + SBRT Anti-PD-1 Ab, vaccine
NCT02558894 II Durvalumab ± tremelimumab Anti-PD-L1 Ab, anti-CTLA-4 Ab
NCT02243371 II GVAX + CRS-207 ± nivolumab Vaccine, anti-PD-1 Ab
Hepatocellular carcinoma
NCT02843802 I/II NK cells + cryosurgery Natural killer cells
NCT02873442 I/II Precision cells + TACE Dendritic cell suspension
NCT02239900 I/II Ipilimumab + SBRT Anti-CTLA-4 Ab
NCT01658878 I/II Nivolumab; nivolumab + ipilimumab Anti-PD-1 Ab, anti-CTLA-4 Ab
NCT02839954 I/II CAR-pNK cell Adoptive cellular therapy
NCT02632006 I/II PIK-PD-1 cells Adoptive cellular therapy
NCT02715362 I/II GPC3-CAR T cells Adoptive cellular therapy
NCT02702414 II Pembrolizumab Anti-PD-1 Ab
NCT02519348 II Durvalumab + tremelimumab vs. durvalumab vs. tremelimumab Anti-PD-L1 Ab, anti-CTLA-4 Ab
NCT02487017 II TACE ± DC-CIK Adoptive cellular therapy
NCT02256514 II Hepcortespenlisimut-L Cancer vaccine
NCT01174121 II Autologous tumor infiltrating lymphocytes (TILs) Adoptive cellular therapy
NCT02562755 III Sorafenib ± Pexa-Vec Vaccinia virus-based cancer vaccine
NCT02576509 III Nivolumab vs. sorafenib Anti-PD-1 Ab
NCT02702401
(KEYNOTE-240)
III Pembrolizumab vs. BSC Anti-PD-1 Ab
NCT02232490 III Hepcortespenlisimut-L vs. placebo Cancer vaccine
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in one of the four DNA MMR genes (MLH1, MSH2,
MSH6, PMS2) or from epigenetic silencing of MLH1
caused by promoter region hypermethylation. This re-
sults in multiple frameshift and missense mutations of
DNA coding sequences, which produce a large number
of aberrant proteins that are recognized as “non-self” an-
tigens and trigger an antitumor immune response [33].
In fact, the overall number of frameshift mutations in a
microsatellite-unstable colorectal tumor has been shown
to correlate with TIL density [34]. Llosa et al. analyzed
the genetics and immune microenvironment of colorec-
tal tumors in parallel and demonstrated that tumors
with high T cell infiltrate had defects in MMR resulting
in MSI [35]. MSI-Hi CRCs were shown to upregulate ex-
pression of several immune checkpoints (PD-1, PD-L1,
CTLA-4, LAG-3, IDO) in the TILs, stroma, or tumor in-
vasive front compartments, enabling the tumor cells to
survive. The MSI-Hi subtype of CRC thus represents an
inherently sensitive population for immunotherapy-
based treatment approaches.
In the first-in-human (FIH) phase I trial of nivolumab
that enrolled treatment-refractory solid tumors, only one
patient showed a durable complete response (CR), and
this was a patient with MSI-Hi CRC [36]. The other 19
CRC patients did not have any tumor response, and all
of these had microsatellite-stable (MSS) disease. A phase
II study evaluated the clinical activity of pembrolizumab
monotherapy in patients with previously treated, pro-
gressive metastatic tumors, with and without MMR defi-
ciency (NCT01876511) [37]. The patients were enrolled
in three cohorts, MMR-deficient CRC, MMR-proficient
CRC, and MMR-deficient non-colorectal tumor cohorts.
In this study, the MMR-deficient CRCs were reported to
have encouraging responses to pembrolizumab. The up-
dated results of 53 patients, including 28 patients in the
MMR-deficient CRC cohort and 25 patients in the
MMR-proficient CRC cohort, were presented at the
2016 ASCO annual meeting [38]. The ORR and DCR
were 50 and 89% for MMR-deficient CRC and 0 and
16% for MMR-proficient CRC, respectively. The median
PFS was not reached for MMR-deficient CRC and was
2.4 months for MMR-proficient CRC (HR = 0.135; 95%
CI, 0.043 to 0.191; P = 0.0001). The median OS was not
reached in the MMR-deficient CRC cohort, as opposed
to 6 months in the MMR-proficient CRC cohort (HR =
0.247; 95% CI, 0.117 to 0.589; P = 0.001). These results
suggest that MMR-deficient CRC tumors receive durable
benefit from anti-PD-1 therapy. Based on these encour-
aging results, a phase II study (KEYNOTE-164,
NCT02460198) and a phase III study (KEYNOTE-177,
NCT02563002) of pembrolizumab in MMR-deficient ad-
vanced CRC are ongoing to confirm these early observa-
tions. MSI-Hi tumors are known to be associated with
high neo-antigenic burden; consequently, the tumor
mutational burden is currently being evaluated as a bio-
marker for PD-1/PD-L1 therapeutic response in CRC [39].
Dual immune checkpoint inhibition with a combin-
ation of anti-CTLA-4 and anti-PD-1 antibodies was ex-
amined in a phase II study (CheckMate-142) that
evaluated nivolumab with or without ipilimumab in
metastatic CRC (NCT02060188). The interim results
demonstrate that the combination of nivolumab plus ipi-
limumab is associated with encouraging clinical activity
especially in the MMR-deficient subgroup (4-month PFS
rate of 80%, 5-month OS rate of 100%) [40].
MMR deficiency occurs in less than 5% of patients
with metastatic CRC [41]. Despite the compelling re-
sponses observed in the MMR-deficient tumors, treat-
ment with immune checkpoint blockade has been
largely disappointing for the vast majority of advanced
CRC patients with MMR-proficient disease [8, 37, 38,
42]. This is unlike gastric cancer, where response to im-
mune checkpoint blockade in MMR-proficient disease
has been observed in a few instances [43]. Ongoing re-
search is focused on understanding why MMR-proficient
CRC remains largely refractory to immune checkpoint
blockade. An important goal is to develop strategies
aimed at improving the sensitivity of MMR-proficient
CRC towards immunotherapy, as they comprise the vast
majority of colorectal tumors. A potential strategy is to
combine immune checkpoint inhibitors with additional
agents/therapies that have immunomodulatory proper-
ties, to stimulate the immune response in the MMR-
proficient tumors. Several ongoing clinical trials are ac-
tively testing this hypothesis.
A phase II study is evaluating the safety and abscopal
effect of pembrolizumab when administered in combin-
ation with radiotherapy or tumor ablation, in patients
with MMR-proficient metastatic CRC (NCT02437071)
[44]. Out of 11 patients in the pembrolizumab plus
radiotherapy cohort, one patient demonstrated PR in the
non-irradiated lesion. No responses were observed
among the eight evaluable patients in the pembrolizu-
mab plus ablation cohort.
In preclinical models, MAPK/ERK kinase (MEK) in-
hibition is associated with upregulation of major histo-
compatibility complex (MHC)-1 on cancer cells and
infiltration of T cells in tumors, leading to enhanced
anti-PD-L1 activity. This formed the basis of a phase Ib
study that combined a MEK inhibitor, cobimetinib, with
an anti-PD-L1 antibody, atezolizumab, in patients with
advanced solid tumors (NCT01988896).The preliminary
results from 23 CRC patients (22 KRAS mutant, 1 wild
type) who have been treated with this combination
showed that four patients (3 MMR-proficient, 1 un-
known) achieved a PR and another five had SD [45].
These promising results have led to the design of a large
phase III study which is evaluating the combination of
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cobimetinib plus atezolizumab in MMR-proficient ad-
vanced CRCs (NCT02788279).
Epigenetic priming using inhibition of histone deacety-
lases (HDAC) and DNA methyltransferases (DNMT)
can induce susceptibility to immune checkpoint therapy
in preclinical models. This is being evaluated in an on-
going pilot study that combines 5-azacitidine (DNMT
inhibitor) or romidepsin (HDAC inhibitor) or both with
the PD-1 inhibitor pembrolizumab in MMR-proficient
advanced CRC (NCT02512172).
Upregulation of immunosuppressive cofactor PD-L1 is
an important mechanism by which tumor cells can es-
cape host T cell immunity. Emerging evidence now sug-
gests that chemotherapeutic agents can regulate PD-L1
expression on cancer cells, which may have an impact
on antitumor immunity and immune evasion [46–48].
Moreover, many chemotherapeutic agents including tax-
anes, gemcitabine, doxorubicin, 5-azacitidine and 5-FU
are known to have immunostimulatory effects in
addition to their conventional cytotoxic activity [49, 50].
For example, 5-FU facilitates antigen expression by
tumor cells, antigen uptake by dendritic cells, and subse-
quent cross-penetration of tumor antigens [51]. There-
fore, combining chemotherapy with an immune
checkpoint inhibitor that can counteract the effects of
PD-L1 is another potential therapeutic strategy that is
being explored in clinical trials (NCT01633970,
NCT02375672, NCT02291289).
Pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a biologic-
ally aggressive disease with a dismal prognosis and lim-
ited therapeutic options. It is the fourth leading cause of
cancer-related death in the USA for both men and
women [10]. In 2016 alone, approximately 53,000 new
cases of pancreatic cancer are estimated to be diagnosed
in the USA, and approximately 42,000 patients will die
from their disease. It is now well established that pancre-
atic cancer carcinogenesis is driven by alteration in mul-
tiple genes that regulate oncogenic pathways in the
tumor cells and the neighboring microenvironment [52,
53]. A prominent histological hallmark of PDAC is des-
moplastic reaction, which results in the formation of
dense stroma in the tumor microenvironment [54]. This
not only presents as a mechanical barrier to immune
cells and the effective delivery of anticancer agents to
the tumor cells but also contributes to the development
of an antiangiogenic, hypoxic, and immunosuppressed
tumor microenvironment. Despite our improved under-
standing of the involved molecular pathways, there has
been no clinically meaningful improvement in the 5-year
survival rates for patients with pancreatic cancer. Conse-
quently, many novel treatment strategies against
pancreatic cancer are currently in preclinical and clinical
development [53].
Several cancer vaccines aimed at stimulating the host
immune system by generating humoral and/or cellular
immune responses have also been evaluated in the treat-
ment of pancreatic cancer. However, this strategy has
not demonstrated a meaningful clinical benefit in any
phase III clinical trial till date. Algenpantucel-L is a
whole-cell allogeneic pancreatic cancer vaccine com-
posed of two irradiated human pancreatic cell lines that
have been engineered to overexpress murine enzyme
alpha(1,3)-galactosyltransferase. In a phase II adjuvant
trial of resected pancreatic cancer, algenpantucel-L dem-
onstrated encouraging activity when combined with ra-
diation, 5-FU, and gemcitabine [55]. This led to a large
phase III adjuvant trial in pancreatic cancer that com-
pared gemcitabine with or without algenpantucel-L
followed by chemoradiation (IMPRESS, NCT01072981).
A total of 722 pancreatic cancer patients who had
undergone surgical resection were enrolled in the study.
The study did not meet its primary endpoint; the me-
dian OS was 30.4 and 27.3 months in the control and
study groups, respectively. Another phase III trial is
examining the role of neoadjuvant FOLFIRINOX or
gemcitabine/nab-paclitaxel with or without
algenpantucel-L, followed by chemoradiation in border-
line resectable or locally advanced unresectable pancre-
atic cancer patients (PILLAR, NCT01836432). The study
has completed its planned enrollment of over 300 pa-
tients in December 2015.
GV1001 is a telomerase peptide vaccine shown to pro-
long survival when combined with granulocyte-
macrophage colony-stimulating factor (GM-CSF) in a
phase I/II study of unresectable pancreatic cancer patients
[56]. However, the phase III study comparing gemcitabine
with or without GV1001 in advanced unresectable pancre-
atic cancer was terminated early due to lack of survival
benefit in the GV1001 arm (NCT00358566). Another
phase III trial has examined the efficacy of GV1001 in
combination with gemcitabine plus capecitabine (TeloVac,
ISRCTN4382138) [57]. The median OS was not statisti-
cally significantly different in the chemotherapy group
than in the chemo-immunotherapy group.
GVAX is composed of allogeneic pancreatic cancer
cells that are genetically modified to secrete GM-CSF.
CRS-207 is a live-attenuated Listeria monocytogenes-
based vaccine that can induce listeriolysin O- and
mesothelin-specific T cell responses. The combination of
GVAX/CRS-207 was shown to extend survival in meta-
static pancreatic cancer patients, in a phase II study [58].
Subsequently, the combination of GVAX/CRS-207 was
evaluated in a larger phase IIb clinical trial (ECLIPSE) of
pretreated advanced pancreatic cancer patients
(NCT02004262). In this open-label, three-arm trial, 303
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patients with metastatic pancreatic cancer were random-
ized to receive either GVAX/CRS-207 combination,
CRS-207 alone, or chemotherapy. This study also failed
to meet its primary endpoint, with the median OS of
3.8, 5.4, and 4.6 months in the three study arms,
respectively.
Wilms’ tumor gene (WT1) is overexpressed in several
malignancies including PDAC. The efficacy of WT1 pep-
tide vaccine plus gemcitabine was examined in a ran-
domized phase II study of locally advanced or advanced
pancreatic cancer patients [59]. In the subgroup of pa-
tients with metastatic disease, the combination of WT1
plus gemcitabine was associated with a superior PFS, as
compared to gemcitabine alone (133 versus 76 days; HR
= 0.48; 95% CI, 0.30–0.77; P = 0.008). IMM-101 is heat-
killed Mycobacterium obuense, which is capable of
modulating the innate and adaptive immune systems in
response to cancer [60]. IMAGE-1 was a randomized
(2:1) phase II study designed to explore the safety and
tolerability of IMM-101 in combination with gemcita-
bine versus gemcitabine alone, as first-line treatment in
advanced pancreatic cancer (NCT01303172) [61]. The
recently reported results confirmed that IMM-101 plus
gemcitabine was as safe and well tolerated as gemcita-
bine alone. Moreover, in the predefined metastatic sub-
group, OS was significantly improved in favor of IMM-
101 plus gemcitabine combination (7.0 versus
4.4 months; HR = 0.54; 95% CI, 0.33–0.87; P = 0.01). It
would be interesting to see whether WT1 peptide vac-
cine and IMM-101 continue to retain their clinical effi-
cacy when tested in large phase III trials.
As in other malignancies, the immunotherapeutic
strategy of targeting the immune checkpoints such as
CTLA-4 and PD-1/PD-L1 is also being evaluated in the
treatment of pancreatic cancer. However, immune
checkpoint blockade by itself has shown limited clinical
responses in pancreatic cancer. For example, a phase II
trial of single-agent ipilimumab failed to demonstrate
any significant antitumor activity in advanced pancreatic
cancer [62]. This is largely attributed to the lack of intra-
tumoral effector T cells and an immunologically quies-
cent microenvironment of pancreatic cancer. Due to the
lack of meaningful clinical benefit of individual immuno-
therapeutic agents against pancreatic cancer, a strategy
of combining immunotherapy with additional therapies
is being actively investigated. The combination of ipili-
mumab plus gemcitabine was evaluated in a phase Ib
dose-finding study of advanced pancreatic cancer
(NCT01473940). Dose escalation was performed in a
standard 3 + 3 fashion. The maximum tolerated dose
(MTD) was established at gemcitabine 1000 mg/m2 plus
ipilimumab 3 mg/kg dose. Out of 16 patients enrolled in
the study, 2 patients experienced PR and 5 had SD. The
median PFS and OS were 2.5 and 8.5 months,
respectively [63]. Checkpoint inhibition is also being
combined with pancreatic cancer vaccines with a goal to
improve the T cell-specific responses. An ongoing phase
II study is comparing combination of GVAX/CRS-207
with or without nivolumab in patients with metastatic
pancreatic cancer who have failed one prior chemother-
apy regimen for metastatic disease (STELLAR,
NCT02243371). In another pilot study, nivolumab is be-
ing combined with dendritic cell vaccine in metastatic
pancreatic cancer. In seven patients who have been
treated till date, two PR have been observed so far [64].
Combined blockade of immune checkpoints is also be-
ing explored in pancreatic cancer. An ongoing phase II
study is evaluating durvalumab with or without tremeli-
mumab in previously treated metastatic pancreatic can-
cer patients (ALPS, NCT02558894). Combining anti-
PD-1 therapy with targeted agents is another therapeutic
strategy. An open-label, randomized phase II study com-
pared the efficacy of a Bruton’s tyrosine kinase (BTK) in-
hibitor, acalabrutinib, with or without pembrolizumab in
patients with metastatic pancreatic cancer
(NCT02362048) [65]. The combination was noted to
have encouraging preliminary activity and an acceptable
side effect profile. In the combination arm, 3 PR and 5
SD were reported among the 23 patients who were eva-
luable for response.
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the second leading cause of
cancer-related deaths in men [66]. Due to its insidious
onset and rapid progression, most cases are detected at
an advanced stage. Infection with hepatitis B virus
(HBV) and hepatitis C virus (HCV), chronic alcoholism,
and fatty liver disease are the major risk factors for
HCC. Recent evidence suggests that the phenomenon of
epithelial-mesenchymal transition (EMT) plays a central
role in the pathogenesis of HCC and is also likely re-
sponsible for the development of metastases, tumor het-
erogeneity, and therapeutic resistance [67]. Currently,
sorafenib, a multi-targeted tyrosine kinase inhibitor
(TKI), is the only systemic agent approved for the treat-
ment of advanced HCC, but the treatment is usually as-
sociated with significant toxicity and confers only a
modest survival benefit [68]. Moreover, no therapeutic
agents are currently approved for sorafenib-resistant dis-
ease. Therefore, there is an urgent unmet need for
breakthrough in systemic treatment of advanced HCC.
Immune checkpoint inhibitors, including anti-CTLA-4
and anti-PD-1 antibodies, are being evaluated in the
treatment of HCC and have demonstrated preliminary
evidence of efficacy with a manageable toxicity profile.
The antitumor and antiviral effect of the anti-CTLA-4
antibody tremelimumab in patients with HCC and
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chronic HCV infection was tested in a pilot clinical trial
(NCT01008358). The PR rate was 17.6% and the DCR
was 76.4% [69]. The time to tumor progression (TTP)
was 6.5 months in this study. A significant drop in viral
load was also observed with tremelimumab therapy. Tre-
melimumab has also been combined with subtotal abla-
tion (trans-arterial chemoembolization (TACE),
radiofrequency ablation (RFA), or cryoablation) in a
study that enrolled HCC and biliary tract cancers
(NCT01853618). So far, 41 patients have been enrolled
in the study, and 4 (23.5%) confirmed PR were observed
among the 17 evaluable patients [70]. The median PFS
in the evaluable HCC patients was 5.7 months. Tumor
biopsies obtained at 6 weeks demonstrated accumulation
of TILs, and there was peripheral blood activation of
CD4+ and CD8+ T cells in the responding patients.
Among the 12 patients with underlying HCV infection,
10 patients experienced a marked reduction in viral load
with the combination therapy. The findings from this
study suggest that tremelimumab combined with sub-
total ablation using TACE, RFA, or cryoablation is safe
and a feasible strategy in the treatment of advanced
HCC.
The anti-PD-1 agent nivolumab is currently being
evaluated in a phase I/II study (CheckMate-040) of ad-
vanced HCC patients who have previously failed, have
refused, or are intolerant of sorafenib (NCT01658878).
In the dose escalation (0.1, 0.3, 1, 3, and 10 mg/kg)
phase of this study, patients with a Child-Pugh score ≤7
were enrolled in three parallel cohorts based on the
underlying disease etiology: no active hepatitis virus in-
fection, HBV-infected, and HCV-infected [71]. The pri-
mary endpoint of the study is safety, and the secondary
endpoints include antitumor activity by RECIST and
DoR. Out of a total of 51 patients in this phase of the
study, TRAEs were observed in 39 patients (77%), with
rash (20%) and elevation in aspartate aminotransferase
(AST; 20%) being the most common. The most common
grade 3–4 TRAEs included elevation of AST (10%), ala-
nine aminotransferase (ALT; 6%), and lipase (6%) levels.
The MTD was not reached in any study cohort. Efficacy
evaluation in 48 patients demonstrated durable treat-
ment response, and disease stabilization was observed
across all dose levels and cohorts. The ORR was deter-
mined at 15% (3 CR, 4 PR), and the median DoR was
23.7 months. In the subsequent dose expansion phase of
this study, 206 patients with advanced HCC were treated
with nivolumab at 3 mg/kg and were enrolled in four co-
horts (uninfected sorafenib-naïve/intolerant, uninfected
sorafenib progressors, HBV-infected, and HCV-infected)
[72]. The grade 3–4 TRAEs were observed in 28 patients
(14%); the most common included elevation in AST and
ALT (3% each). A decline in tumor burden was observed
in 39% patients. Preliminary efficacy results show an
ORR of 9% among 91 evaluable patients. The 6-month
OS rate was 69% (95% CI, 0.43–0.85). Responses were
observed independent of the tumor PD-L1 expression.
Based on the encouraging preliminary data from the
CheckMate-040 trial, a randomized phase III study com-
paring the efficacy of nivolumab versus sorafenib in ad-
vanced HCC was designed and is currently ongoing
(CheckMate-459, NCT02576509).
Anticancer vaccines are also being actively tested in
the treatment of HCC. For example, Pexa-Vec (pexasti-
mogene devacirepvec) is an oncolytic and immunothera-
peutic vaccinia virus that disrupts tumor vasculature
and mediates antitumor immunity via GM-CSF expres-
sion. In a randomized phase II dose-finding trial, intratu-
moral injection of Pexa-Vec in advanced HCC patients
demonstrated an acceptable safety profile and a signifi-
cant increase in OS in the high-dose group [73, 74]. A
randomized phase III study to compare the efficacy and
tolerability of Pexa-Vec followed by sorafenib versus so-
rafenib alone in patients with advanced HCC is currently
ongoing (PHOCUS, NCT02562755). Another oral thera-
peutic vaccine, hepcortespenlisimut-L, is currently being
evaluated in an ongoing phase III clinical trial
(NCT02232490) after it demonstrated encouraging ac-
tivity in the phase II study [75].
Conclusions
GI malignancies have been traditionally considered to be
poorly immunogenic; however, increasing evidence now
suggests that these tumors are recognized by the im-
mune system. Immune checkpoint blockade with anti-
bodies targeting B7 immunoglobulin superfamily
molecules such as CTLA-4, PD-1, and PD-L1 is showing
promising clinical activity in multiple GI tumors includ-
ing esophageal, gastric, colorectal, and liver cancers. In
fact, one of the most significant achievements witnessed
in the field of immunotherapy has been the success of
PD-1 pathway blockade in MSI-Hi colorectal and non-
colorectal tumors [76]. The therapeutic strategy of com-
bining immune checkpoint inhibitors with additional
immunostimulatory therapies, targeted agents, chemo-
therapy drugs, or radiotherapy appears to be a promising
approach that might help further unleash the antitumor
immunity against several types of GI cancers. However,
treatment with such immunostimulatory therapies is not
completely devoid of side effects, and cases of potentially
fatal immune-related adverse events have been reported
[77, 78]. The identification of clinically relevant predict-
ive and prognostic biomarkers will therefore help define
subgroups of GI cancer patients who are most likely to
benefit from various immunotherapeutic approaches
[79]. This is critical for the success of immunotherapy
and is therefore the focus of ongoing translational re-
search in the field.
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